• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

Discuss Meningitis B vaccine

Extracts from this document...


In this assignment, I would like to discuss about Meningitis B vaccine, the vaccine which is licensed for use in New Zealand but is not on the national immunization schedule. I will also briefly describe the disease it prevents, New Zealand epidemiology. The vaccine will also be described in term of vaccine efficacy, usage, administration, contraindication and side effects. Lastly, there will be the including the vaccine in the schedule. 1. WHAT IS MENINGOCOCCAL DISEASE? Meningococcal disease is an illness caused by the bacteria Neisseria meningitidis. At least 13 groups of meningococci can be differentiated based on the chemical and immunological properties of the capsular polysaccharides. The meningococcus has five main groups are A, B, C, w135 and Y. In New Zealand, group B meningococcal disease accounts for the majority of cases around 93%. Group C around 6% group Y accounts for a small number of cases in each year and group A rarely causes disease (MOH, 2004). The two common of meningococcal infection are meningococcal meningitis which of the membranes that surround the brain and the spinal cord. And the meningococcemia is the infection of the blood stream. ...read more.


wall of the New Zealand strain of meningococci. MeNZB vaccine contains: aluminum hydroxide as the adjuvant, histadine buffer to stabilize the pH of the vaccine and normal saline (Peltola, 1998). 6. PREVENTION The epidemic strain of meningococcal disease that the targeted by MeNZB vaccine continues to causes the majority of meningococcal disease cases. The introduction of the MeNZB vaccine will significantly impact on the number of notified cases of epidemic train group B meningococcal disease during 2005 with the likely continuance in the background rates for other serogroups and sub-strains of serogroup B meningococcal disease (MOH, 2004). However, the Meningococcal B Immunization Program has commenced in the highest risk areas of New Zealand and will continue to be rolled out during 2005 throughout the rest of the country (MOH, 2004). 7. CLINICAL EFFICACY MeNZB vaccine may not protect every person who receives the three doses nut it is expected that most people will be protected. While the exact period is unknown, protection is expected to last for a number of years. Data from trials using a vaccination schedule of 3 doses MeNZB given with an interval of 6 weeks demonstrate that 55% of infants (6 weeks), 74% older infants( 6 weeks), 75% toddlers, 76% children, and 93% adults developed a 4-fold rise(compared with pre-vaccination values) ...read more.


Most infants had normal body temperature by the second day after vaccination. 11. DISCUSSION A vaccination schedule of three (four for infants) doses MeNZB given with an interval of 6 weeks between doses induces a humoral immune response against the New Zealand strain. Infants are the group at highest risk of the epidemic strain of group B meningococcal disease. It is therefore recommended that the first three MeNZB vaccine doses be given concurrently with other childhood vaccines: * Dose 1 at six weeks of age * Dose 2 at three months of age (13 weeks of age) * Dose 3 at five months of age (at least 21 weeks of age) And then: Dose 4 at 10 months of age (at least 43 weeks) These dose intervals are to ensure the MeNZB vaccine stimulates the optimum immune response as recorded in the clinical trials, while offering protection as early as possible. REFFERENCES http://www.moh. Meningococcal B disease. (2004). http://www. everybody.co.nz/docsip/ meningitis.html. (2004) Meningitis and meningococcal disease. MOH. (2002). Immunization handbook. Wellington: New Zealand. Peltola, H. (1998). Meningococcal vaccines. Drugs. 55:347-366. Sexton, K., Lennon, D., Oster, P., Crengle, S., Martin, D., Mulholland, K., Percival, T., Reid, S., Stewart, J. & O'Hallahan, J. (2004).The New Zealand Meningococcal Vaccine Strategy: A tailormade vaccine to combat a devastating epidemic. The New Zealand Medical Journal, 1200: 1- 9. ?? ?? ?? ?? Christy Tran 1 ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our University Degree Problem Based Learning cases section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related University Degree Problem Based Learning cases essays

  1. Clinical care case study. Mrs. Burton was left with a mixture of emotion mostly ...

    Overall with Mrs. Burton's case it has highlighted key issues which has alarmed me that as a student nurse, it is essential to be able to provide time for patients in order for person centre care to work effectively by following the National service framework for mental health: modern standards and service models (1999)

  2. Praxis Note on Alzheimer's Disease

    The Diagnostic and Statisical Manual of Mental Disorders has defined a set of criteria for the diagnosis of AD: probable AD, Possible AD, Definite AD. The individual with AD must show signs of cognitive impairment that is severe enough to interfere with daily life (Belavic, 2009).

  1. Origin,causes and treatments of gastroenteritis using a case study

    � Fever. � b****y diarrhoea. � Abdominal pain and tenderness. � Diarrhoea lasting more than 10 days. � Increased risk of poor outcome, for example: - Coexisting medical conditions - immunodeficiency, lack of stomach acid, inflammatory bowel disease, valvular heart disease, diabetes mellitus, renal impairment, rheumatoid disease, systemic lupus erythematosus.

  2. Anaphylactoid reactions from Iopromide in patient with angina undergoing angiography - Pharmacovigilance Brief Report ...

    This similarity underpins the similar treatment for both reactions. Management of anaphylactoid reactions should relieve the symptoms in acute episode. Recommended acute management of a patient with anaphylaxis is to place the patient in a supine position and give adrenaline and intravenous volume resuscitation (Level IV).

  1. With medical advances promising ever more detailed pre-natal genetic screening, do we have a ...

    The second major point in this debate is that of the obligations of the medical profession in such cases. Glannonviii states that medical practice is grounded in the principles of nonmalefience (not harming), Benefience (bringing benefit), Autonomy (individual self determination), and Justice (the right to fair and equal treatment).

  2. Should my child have the MMR vaccination?

    (Source http://www.paains.org.uk/Autism/whatisautism.htm) The link between the MMR vaccination and autism When did the link between MMR and autism occur? The theory came around when Dr Andrew Wakefield: of the Royal free hospital suggested that common childhood vaccine may be linked with autism and cause an intestinal disorder.

  1. MMR Jab - Vaccine or Poison

    He was then transferred to London Great Ormond Street for brain surgery. Samples of his brain tissue where analysed, the results showed traces of the Measles virus "consistent" with the vaccine rather than the "wild" strain. Tissue also from the same boys intestine showed the vaccine.

  2. This report aims to outline the processes, eligibility criteria and Medicare funding involved with ...

    development ? as well as children?s social and emotional behaviours? (Cabrera, Shannon, & Tamis-LeMonda, 2007). However, proponents argue the right of the mother to reproduce, as discussed above, thus the mother?s rights may infringe on the child?s rights. Whether the mother?s right to reproduce and have a family precedes the

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work